.jpg?format=webp&width=780)
A study assessed fluvoxamine's efficacy in treating mild to moderate COVID-19. Over 1,100 participants were randomized to receive fluvoxamine or a placebo. Surprisingly, there were no significant differences in symptom duration between the groups. Both took a median of 10 days to recover. These findings suggest that fluvoxamine may not substantially reduce symptom duration in outpatients with mild to moderate COVID-19.
Like
Save
Share